Dynavax Technologies Corporation is a commercial stage biopharmaceutical company developing vaccines for US markets. It markets HEPLISAV-B, a hepatitis B vaccine, and manufactures CpG 1018, its adjuvant. The company has collaborations with various partners globally. Previously known as Double Helix Corporation, it changed its name to Dynavax Technologies in September 1996. Founded in 1996, the company is headquartered in Emeryville, California. It markets HEPLISAV-B for prevention of hepatitis B infection.
| Indicator | Value |
|---|---|
| PER | 45.7 |
| EV/EBITDA | 30.8 |
| Price/Free Cash Flow' | 20.7 |
| ROIC | 7.8% |
| Net Debt/EBITDA | 3.5 |